AbbVie Inc. (NYSE: ABBV) will not pursue accelerated approval for Rova-T to treat small cell lung cancer. The stock price crashed $14.35 to close at $98.10.
No accelerated approval for AbbVie's Rova-T
March 22, 2018 at 17:39 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|